 | Up a level |
Journal Article
Abduljalil, K., Frank, D., Gaedigk, A., Klaassen, T., Tomalik-Scharte, D., Jetter, A., Jaehde, U., Kirchheiner, J. and Fuhr, U. (2010). Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan. Clin. Pharmacol. Ther., 88 (5). S. 643 - 652. NEW YORK: NATURE PUBLISHING GROUP. ISSN 0009-9236
Arshad, U., Taubert, M., Kurlbaum, M., Frechen, S., Herterich, S., Megerle, F., Hamacher, S., Fassnacht, M., Fuhr, U. and Kroiss, M. (2018). Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients. Eur. J. Endocrinol., 179 (5). S. 287 - 298. BRISTOL: BIOSCIENTIFICA LTD. ISSN 1479-683X
Dahlinger, D., Frechen, S., Aslan, S. and Fuhr, U. (2015). In Vitro Assessment of Direct and Time-Dependent Inhibitory Effects on Major Human Cytochrome P450 Enzymes by Spasmolytics. Naunyn-Schmiedebergs Arch. Pharmacol., 388. S. S49 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Dahlinger, D., Frechen, S., Aslan, S. and Fuhr, U. (2015). In Vitro Assessment of Direct and Time-Dependent Inhibitory Effects on Major Human Cytochrome P450 Enzymes by Spasmolytics. Naunyn-Schmiedebergs Arch. Pharmacol., 388. S. S49 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Frechen, S., Suleiman, A. A., Sigaroudi, Mohammad Nejad A., Wachall, B. and Fuhr, U. (2015). Population Pharmacokinetic and Pharmacodynamic Modeling of Epinephrine administered using a Mobile Inhaler. Naunyn-Schmiedebergs Arch. Pharmacol., 388. S. S51 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Frechen, S., Suleiman, A. A., Sigaroudi, Mohammad Nejad A., Wachall, B. and Fuhr, U. (2015). Population Pharmacokinetic and Pharmacodynamic Modeling of Epinephrine administered using a Mobile Inhaler. Naunyn-Schmiedebergs Arch. Pharmacol., 388. S. S51 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Hsin, C. H., Kinzig, M., Schaeffeler, E., Lenssen, R., Taubert, M., Trueck, C., Gazzaz, M., Quasdorff, M., Schwab, M., Soergel, F., Stoffel, M. and Fuhr, U. (2018). Lack of mutual pharmacokinetics DDIS for a novel transporter phenotyping cocktail. Naunyn-Schmiedebergs Arch. Pharmacol., 391. S. S44 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Hsin, C. H., Stoffel, M., Gazzaz, M., Schaeffeler, E., Schwab, M., Li, X., Fuhr, U. and Taubert, M. (2020). Haplotypes of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin. Naunyn-Schmiedebergs Arch. Pharmacol., 393 (SUPPL 1). S. 78 - 79. NEW YORK: SPRINGER. ISSN 1432-1912
Nogova, L., Gardizi, M., Bos, M., Scheffler, M., Papachristou, I., Woempner, C., Heukamp, L., Schildhaus, H. -U., Fuhr, U., Sos, M., Eberhardt, W., Wiesweg, M., Schmid, K. W., Schuler, M., Thomas, R., Buettner, R. and Wolf, J. (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Nogova, L., Mattonet, C., Gardizi, M., Scheffler, M., Bos, M., Woempner, C., Toepelt, K., Heukamp, L., Suleiman, A., Frechen, S., Soergel, F., Fuhr, U., Schnell, R., Katay, I., Behringer, D., Geist, T., Kaminski, B., Eichstaedt, M., Tummes, D., Buettner, R. and Wolf, J. (2014). SORAVE: Sorafenib and everolimus for patients with solid tumors and with KRAS mutated NSCLC - results of a phase I study. Oncol. Res. Treat., 37. S. 32 - 33. BASEL: KARGER. ISSN 2296-5262
Queckenberg, Christian, Erlinghagen, V., Baken, B. C. M., Van Os, S. H. G., Wargenau, M., Kubes, V., Peroutka, R., Novotny, V. and Fuhr, U. (2015). Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations. Cancer Chemother. Pharmacol., 76 (5). S. 1081 - 1092. NEW YORK: SPRINGER. ISSN 1432-0843
Sigaroudi, A., Kinzig, M., Wahl, O., Schroeter, M., Stelzer, C., Fuhr, U., Holzgrabe, U. and Soergel, F. (2017). Comparison of hydrochlorothiazide and ramipril concentrations in simultaneous cerebrospinal fluid and blood serum samples. Naunyn-Schmiedebergs Arch. Pharmacol., 390. S. S9 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Suleiman, A. A., Schoettle, J., Jaehde, U., Ullrich, R. and Fuhr, U. (2016). High-pulsed doses of erlotinib for the treatment of non-small-cell lung cancer: A modeling analysis. Naunyn-Schmiedebergs Arch. Pharmacol., 389 (1). S. S70 - 2. NEW YORK: SPRINGER. ISSN 1432-1912
Taubert, M., Ebert, N., Martus, P., van der Giet, M., Fuhr, U. and Schaeffner, E. (2020). Simplification and validation of a three-compartment model of iohexol to estimate plasma clearance in patients with impaired kidney function. Naunyn-Schmiedebergs Arch. Pharmacol., 393 (SUPPL 1). S. 79 - 80. NEW YORK: SPRINGER. ISSN 1432-1912
Taubert, M., Lueckermann, M. and Fuhr, U. (2017). Population pharmacokinetics of finafloxacin in healthy volunteers and patients suffering from urinary tract infections. Naunyn-Schmiedebergs Arch. Pharmacol., 390. S. S16 - 1. NEW YORK: SPRINGER. ISSN 1432-1912
Trueck, C., Gazzaz, M., Kinzig, M., Schaeffeler, E., Kinzig, M., Juebner, M., Hsin, C. H., Li, X., Taubert, M., Iltgeb-Breburda, J., Kraus, D., Queckenberg, C., Stoffel, M., Schwab, M., Soergel, F. and Fuhr, U. (2018). A cocktail study to assess pharmacokinetic interactions of acute ethanol intake. Naunyn-Schmiedebergs Arch. Pharmacol., 391. S. S24 - 1. NEW YORK: SPRINGER. ISSN 1432-1912